Marzeptacog alfa - Catalyst Biosciences

Drug Profile

Marzeptacog alfa - Catalyst Biosciences

Alternative Names: CB 813; CB 813d; MarzAA; marzeptacog alfa; Marzeptacog alpha; PF-05280602; PF-5280602; Recombinant Factor VIIa variant (813d)

Latest Information Update: 06 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Catalyst Biosciences
  • Class Antihaemorrhagics; Blood coagulation factors; Peptide hydrolases; Recombinant proteins
  • Mechanism of Action Factor VIIa stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemophilia
  • Phase I Surgical blood loss

Most Recent Events

  • 04 Sep 2018 Pharmacokinetics and Efficacy data from a phase I trial in Haemophilia released by Catalyst Biosciences
  • 15 Aug 2018 Interim efficacy data from a phase II/III trial in Haemophilia released by Catalyst Biosciences
  • 19 Jul 2018 Efficacy and pharmacokinetics data from a phase II/III trial in Haemophilia released by Catalyst Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top